Calcbench

Grocery giant Kroger ($KR) filed its full-year 2025 earnings release this morning, with a rather unpleasant $2.5 billion impairment charge for a warehouse automation project that never delivered on its expected promises. The impairment charge wasn’t a surprise. Kroger had previously disclosed the matter in a filing on Nov. 18 , framing the matter as an “updated e-commerce plan” where Kroger would close three fulfillment warehouses around the United States. The impairment translates to a one-time hit to EPS of $2.91 per diluted share. Wait a minute, warehouse automation costs… Why does that ring a bell?  Because Walmart ($WMT) reported its own EPS issues with warehouse automation several weeks ago — but did so in a very different way. Together, the two earnings releases present a fascinating comparison of how large businesses might treat projects and how they disclose issues to investors when said project goes wobbly. First, Kroger. The company originally struck a partnership in...

Provision for Loan Losses as Percentage of Revenue, 2023-2025 Provisions for loan losses (PLL) is a valuable insight into the strength of financial firms' growth prospects. Calcbench allows users to plot PLL as a percentage of revenue over time to see which firms have significant shifts in PLL, which can be a leading indicator of potential lending trouble. The below chart shows PLL as percentage of revenue for 28 financial firms for the last three years. Some firms have two or one dots when the year-over-year percentages are unchanged. Calcbench subscribers can find this data in several ways. You could use our Multi-Company page to track revenue and PLL for any group of companies you like (although PLL is mostly a disclosure for financial firms) and then ask for a time-series of data for both metrics. You could also configure a template with our Excel Add-In. For Premium subscribers, the data would automatically populate i...

Net Income +10.2% YoY change, Q4 2025 vs. Q4 2024 Revenue +8.5% YoY change, Q4 2025 vs. Q4 2024 Cash +9.8% YoY change, Q4 2025 vs. Q4 2024 We are just about at the end of Q4 and full-year earnings season, and this Friday have perhaps our last earnings roundup of the season courtesy of the famed Calcbench Earnings Tracker.  We now have more than 2,000 non-financial firms in our sample, including important late filers such as Walmart ($WMT) and Nvidia ($NVDA), which just filed two days ago. Figure 1, below, shows the change in Q4 2025 numbers from the year-ago period. Most notably, net income is up 10.2 percent from one year ago, revenue up 8.5 percent. EBIT, operating income, and cash from operations are all up by double-digits too. Cash is up 9...

You may have seen headlines lately that pharmaceutical giant Novo Nordisk ($NVO) will enact significant price cuts for its blockbuster weight loss drugs Ozempic, Wegovy, and Rybelsus starting in 2027. Novo Nordisk is cutting prices because it’s facing stiff competition from Eli Lilly &Co. ($LLY) and pressure from government regulators to make the popular drugs more affordable. The cuts will lower the price for a one-month supply to $675, which translates into reductions of from 35 to 50 percent depending on the exact drug.  For financial analysts, an important question emerges: Just how much money does Novo Nordisk make from these drugs, anyway? As always, Calcbench can help. Novo Nordisk is based in Denmark, and as a foreign issuer its annual report is known as a Form 20-F. In that report, however, the company does report the sales of individual drugs just like U.S. pharmaceutical companies do. (We have a pharmaceutical sales template available for Calcbench premium subscr...

Reading the Signals: Why Meta Borrows While Swimming in Cash Meta 3%  How much Free Cash Flow is left after deducting  Share Repurchasing Spend and Equity Withholding Taxes Alphabet 19% How Much Free Cash Flow is left after deducting Share Repurchasing and Equity With Holding Taxes